A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796 on ClinicalTrials.gov · last registry update 2026-09-30

An unusually large phase 3: 3,400 participants, more than double the 424 typical for the stage. The sponsor logged completion for 30 October 2024. Primary outcome, as filed: CagriSema versus placebo: Relative change in body weight. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 3,400
Started: 2022-11-01
Primary completion: 2024-10-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

CagriSema versus placebo: Relative change in body weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.